Jubilant Pharmova Limited

NSE: JUBLPHARMA · Healthcare

₹939.60-0.79%06 Nov 2026

Ask the data

Instant answers about Jubilant Pharmova Limited — computed from its filings, no language model

Market cap₹14,846 cr

Current price₹939.60

High / Low₹1,181 / ₹808

P/E42.2

P/B2.09

Book value₹448.9

ROE5.0%

ROCE7.4%

Debt / equity0.45

Dividend yield0.54%

EPS (TTM)₹22.28

Face value₹1

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

showing latest 6 of 8 periods

	FY18	FY20	FY21	FY22	FY23	FY24	FY25	FY26
Revenue	7,465	9,154	6,099	6,059	6,282	6,703	7,234	8,280
EBITDA	1,425	1,947	1,396	1,085	776	901	1,174	1,260
Operating margin	19.1%	21.3%	22.9%	17.9%	12.4%	13.4%	16.2%	15.2%
Interest	284	287	184	145	188	272	240	212
Depreciation	415	462	349	382	554	382	369	440
Profit before tax	859	1,211	860	640	16	146	981	614
Tax	225	312	297	217	93	98	144	217
Net profit	0	898	836	414	-61	77	839	398
EPS ₹	41.25	56.39	52.48	26.00	-3.83	4.87	52.99	25.15
Operating cash flow	—	—	—	838	661	971	1,072	1,227
Capex	—	—	—	600	814	898	1,116	1,449
Dividend paid	—	—	—	80	80	80	80	80
Total assets	—	—	—	—	11,157	11,548	12,756	15,523
Equity	—	—	—	—	5,399	5,434	6,255	7,093

Quarterly performance

last 30 quarters · ₹ crore

showing latest 8 of 30 periods

	MAR '18	SEP '18	DEC '18	SEP '19	DEC '19	MAR '20	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	SEP '22	DEC '22	MAR '23	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26
Revenue	2,224	2,269	2,377	2,266	2,315	2,391	1,893	2,375	1,771	1,580	1,635	1,657	1,311	1,514	1,600	1,553	1,678	1,587	1,680	1,677	1,759	1,732	1,752	1,822	1,929	1,901	1,966	2,122	2,290	2,229
Operating profit	430	450	493	468	507	537	302	486	493	375	375	340	194	234	219	146	219	170	242	218	271	252	289	287	345	290	341	290	339	248
Operating margin	19.3%	19.8%	20.8%	20.7%	21.9%	22.4%	16.0%	20.5%	27.8%	23.7%	23.0%	20.5%	14.8%	15.5%	13.7%	9.4%	13.1%	10.7%	14.4%	13.0%	15.4%	14.5%	16.5%	15.8%	17.9%	15.2%	17.4%	13.6%	14.8%	11.1%
Other income	51	4	29	12	6	19	8	7	4	7	4	4	6	10	13	9	4	9	10	36	14	14	22	9	12	12	10	20	24	20
Interest	72	63	68	72	72	71	76	64	46	43	35	35	37	40	42	51	56	62	66	71	73	71	61	56	53	49	50	56	56	54
Depreciation	182	89	98	117	113	129	112	116	96	86	88	100	93	101	94	94	271	90	97	95	101	91	91	91	95	98	105	121	117	127
Profit before tax	227	302	356	292	293	356	122	314	343	241	256	209	70	104	39	10	-103	27	89	88	-57	500	144	131	206	154	190	94	176	86
Tax	74	92	88	43	90	95	34	90	121	83	86	65	19	47	31	25	14	19	36	35	8	18	42	30	55	52	70	38	57	30
Net profit	0	210	261	249	203	260	88	224	310	214	161	143	51	60	5	-16	-98	6	62	67	-59	482	103	101	154	103	120	56	119	56
EPS ₹	9.94	13.50	16.74	15.66	12.77	16.35	5.53	14.06	19.46	13.43	10.09	8.97	3.20	3.74	0.34	-0.98	-6.15	0.40	3.94	4.22	-3.69	30.44	6.47	6.37	9.71	6.49	7.59	3.52	7.55	3.57
Revenue YoY	—	—	—	-0.2%	-2.6%	—	—	4.8%	-23.5%	-33.9%	-13.6%	-30.2%	-26.0%	-4.1%	-3.5%	18.5%	10.8%	—	5.1%	8.0%	4.8%	9.1%	4.3%	8.6%	9.7%	9.8%	12.2%	16.5%	18.7%	17.3%
Profit YoY	—	—	—	18.5%	-22.0%	—	—	-10.2%	52.4%	-17.9%	82.4%	-36.2%	-83.5%	-72.2%	-96.2%	-130.7%	-264.3%	—	1038.4%	—	—	7432.8%	64.5%	51.0%	—	-78.7%	17.0%	-44.6%	-22.3%	-45.1%

Earlier results (standalone, Sep '07 – Dec '17)

₹ crore · from BSE, before the NSE XBRL filings begin

Jubilant Pharmova Limited reports consolidated figures above. Quarterly consolidated results only became mandatory in India in 2019, so the earlier history available is the standalone company only (excluding subsidiaries). It is shown separately so the two bases are never mixed.

Full years

showing latest 8 of 9 periods

	FY09†	FY10†	FY11†	FY12†	FY13†	FY14†	FY15†	FY16†	FY17†
Revenue	2,434	2,460	2,503	2,628	3,150	3,673	3,176	2,656	2,591
Operating profit	430	635	477	411	454	572	274	341	318
Operating margin	17.7%	25.8%	19.1%	15.6%	14.4%	15.6%	8.6%	12.8%	12.3%
Other income	15	12	5	9	9	15	109	62	52
Interest	54	100	47	154	171	247	227	202	174
Depreciation	75	65	102	132	152	175	107	87	81
Profit before tax	-34	459	330	-46	-13	-68	246	91	115
Tax	12	96	29	35	31	-69	41	12	35
Net profit	-46	363	301	-81	-43	1	205	79	79

Quarters

showing latest 8 of 42 periods

	SEP '07†	DEC '07†	MAR '08†	JUN '08†	SEP '08†	DEC '08†	MAR '09†	JUN '09†	SEP '09†	DEC '09†	MAR '10†	JUN '10†	SEP '10†	DEC '10†	MAR '11†	JUN '11†	SEP '11†	DEC '11†	MAR '12†	JUN '12†	SEP '12†	DEC '12†	MAR '13†	JUN '13†	SEP '13†	DEC '13†	MAR '14†	JUN '14†	SEP '14†	DEC '14†	MAR '15†	JUN '15†	SEP '15†	DEC '15†	MAR '16†	JUN '16†	SEP '16†	DEC '16†	MAR '17†	JUN '17†	SEP '17†	DEC '17†
Revenue	493	494	534	616	679	590	549	610	630	616	605	686	673	581	563	619	631	678	701	743	745	817	846	824	928	951	971	1,036	701	715	724	669	707	647	633	587	606	638	760	710	734	934
Operating profit	108	115	121	146	154	105	25	156	158	163	159	139	138	109	91	124	111	110	66	121	123	129	81	110	174	171	117	135	45	47	47	73	97	86	84	92	76	67	83	72	111	191
Operating margin	21.9%	23.3%	22.6%	23.7%	22.6%	17.8%	4.6%	25.5%	25.1%	26.5%	26.2%	20.3%	20.6%	18.7%	16.1%	20.1%	17.5%	16.2%	9.4%	16.2%	16.6%	15.8%	9.6%	13.4%	18.8%	17.9%	12.1%	13.0%	6.5%	6.6%	6.5%	11.0%	13.7%	13.4%	13.3%	15.7%	12.6%	10.4%	10.9%	10.2%	15.2%	20.5%
Other income	31	16	-23	3	6	1	4	2	3	4	3	1	0	1	3	2	2	2	2	2	3	2	2	2	3	2	8	8	52	26	23	13	38	6	4	5	24	13	10	11	22	6
Interest	5	6	2	5	8	14	27	29	26	27	18	6	9	15	17	30	36	42	46	45	43	40	43	48	66	69	64	63	61	56	47	58	53	45	47	44	45	42	43	35	33	34
Depreciation	14	14	21	17	18	19	21	16	16	17	17	25	26	25	26	28	29	32	43	36	37	38	41	43	44	45	44	41	21	23	23	21	22	22	22	20	20	21	20	20	21	21
Profit before tax	120	109	66	19	-10	2	-46	166	82	85	127	97	112	76	45	66	6	-116	-3	-63	95	-19	-26	-102	-81	65	49	191	287	-10	-221	13	48	16	14	32	35	17	30	27	78	143
Tax	8	24	8	5	15	23	-30	21	26	14	35	17	14	4	-6	12	1	21	0	10	12	6	2	4	-2	-99	28	-13	70	-2	-14	6	-3	-12	22	11	11	9	5	5	21	45
Net profit	112	85	57	15	-24	-21	-15	145	55	71	92	80	98	71	52	54	5	-137	-3	-74	84	-25	-28	-106	-79	165	21	204	217	-8	-207	7	51	28	-7	21	24	8	26	22	57	98
EPS ₹	7.79	5.92	3.94	0.99	-1.65	-1.44	-1.04	9.83	3.74	—	6.23	5.05	6.16	4.48	3.25	3.38	0.31	-8.60	-0.17	-4.62	5.25	-1.58	-1.77	-6.65	-4.93	10.33	1.30	12.79	13.61	-0.53	-12.99	0.46	3.20	1.77	-0.47	1.32	1.51	0.52	1.62	1.40	3.57	6.15
Revenue YoY	—	—	—	—	37.7%	19.2%	2.8%	-1.0%	-7.3%	4.5%	10.1%	12.4%	6.8%	-5.6%	-6.8%	-9.8%	-6.2%	16.6%	24.4%	20.0%	18.0%	20.5%	20.7%	10.9%	24.6%	16.4%	14.8%	25.8%	-24.4%	-24.8%	-25.4%	-35.4%	0.9%	-9.5%	-12.6%	-12.3%	-14.3%	-1.4%	20.1%	21.0%	21.1%	46.4%
Profit YoY	—	—	—	—	-121.8%	-124.9%	-126.8%	899.5%	—	—	—	-44.7%	76.3%	1.2%	-43.8%	-32.8%	-94.9%	-291.9%	-105.4%	-236.6%	1572.0%	—	—	—	-194.0%	—	—	—	—	-105.2%	-1096.6%	-96.4%	-76.5%	—	—	183.5%	-52.6%	-70.7%	—	6.2%	135.8%	1085.0%

Returns & margins

trailing-twelve-month, per quarter

showing latest 8 of 21 periods

	JUN '20	SEP '20	DEC '20	MAR '21	JUN '21	SEP '21	DEC '21	MAR '22	JUN '23	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26
ROE	—	—	—	—	—	—	—	—	-1.9%	-0.8%	0.7%	1.4%	10.2%	10.0%	10.6%	13.4%	7.4%	7.2%	6.6%	5.6%	5.0%
ROCE	—	—	—	—	—	—	—	—	2.1%	2.9%	4.0%	4.7%	10.2%	10.9%	11.2%	14.1%	9.8%	9.7%	9.3%	8.0%	7.4%
Net margin	9.0%	8.6%	10.5%	11.0%	12.3%	12.5%	9.2%	6.8%	-1.6%	-0.7%	0.6%	1.2%	8.1%	8.6%	8.9%	11.6%	6.2%	6.3%	5.5%	4.8%	4.1%
EBITDA margin	20.5%	20.4%	21.6%	21.7%	23.5%	23.8%	20.8%	18.7%	11.7%	12.0%	12.8%	13.4%	14.4%	14.9%	15.6%	16.2%	16.4%	16.6%	16.0%	15.2%	14.2%
Debt / equity	—	—	—	—	—	—	—	—	0.63	0.63	0.63	0.63	0.63	0.48	0.48	0.39	0.39	0.39	0.39	0.45	0.45
Interest coverage	4.66	4.83	5.41	5.44	7.13	7.60	6.21	5.40	0.87	1.10	1.39	1.54	3.20	3.44	3.75	5.08	3.91	4.29	4.10	3.90	3.52
Asset turnover	—	—	—	—	—	—	—	—	0.58	0.57	0.58	0.58	0.59	0.58	0.59	0.57	0.58	0.56	0.59	0.53	0.55

Balance sheet

equity vs borrowings over time · ₹ crore

showing latest 6 of 8 periods

	SEP '22	MAR '23	SEP '23	MAR '24	SEP '24	MAR '25	SEP '25	MAR '26
Share capital	16	16	16	16	16	16	16	16
Other equity / reserves	5,460	5,383	5,394	5,418	5,925	6,239	6,576	7,077
Total equity	5,476	5,399	5,410	5,434	5,940	6,255	6,592	7,093
Borrowings	3,219	3,410	3,420	3,414	2,825	2,437	2,599	3,220
Current liabilities	1,491	1,772	1,790	1,889	1,947	2,165	2,088	2,539
Non-current liabilities	3,743	3,992	4,208	4,238	4,051	4,353	4,861	5,888
Total assets	10,705	11,157	11,400	11,548	11,924	12,756	13,521	15,523
Property, plant & equipment	2,240	2,298	2,250	2,158	2,128	2,132	3,242	3,510
Capital work-in-progress	487	773	1,095	1,252	1,857	2,715	2,344	2,962
Investments	46	256	266	42	42	44	45	61
Inventories	1,410	1,381	1,328	1,290	1,162	1,129	1,228	1,232
Receivables	944	961	904	916	795	892	961	1,070
Cash & equivalents	846	1,014	974	956	1,077	1,088	623	1,267

Cash flow

annual · ₹ crore · line = free cash flow

	FY22	FY23	FY24	FY25	FY26
Cash from operations	838	661	971	1,072	1,227
Cash from investing	-380	-544	-608	488	-1,260
Cash from financing	-33	-157	-432	-1,453	95
Capex	600	814	898	1,116	1,449
Free cash flow	238	-154	74	-44	-222
Dividends paid	80	80	80	80	80

Where the assets sit

Mar '26 · ₹ crore

Fixed assets (PPE)

₹3,510 cr23%

CWIP

₹2,962 cr19%

Investments

₹61 cr0%

Inventories

₹1,232 cr8%

Receivables

₹1,070 cr7%

Cash & equivalents

₹1,267 cr8%

Other assets

₹5,422 cr35%

Peer comparison

largest in Healthcare · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Sun Pharmaceutical Industries Ltd.	4,46,270	1,860.00	40.7	5.00	12.3%
Divi's Laboratories Ltd.	2,73,493	10,320.50	93.5	16.32	17.5%
Torrent Pharmaceuticals Ltd.	1,80,671	4,750.00	85.1	9.83	11.6%
Laurus Labs Ltd.	1,26,430	2,340.00	94.4	20.86	22.1%
Apollo Hospitals Enterprise Ltd.	1,21,453	8,446.00	54.2	11.45	21.1%
Zydus Lifesciences Ltd.	1,19,550	1,197.90	28.6	4.30	15.0%
Dr. Reddy's Laboratories Ltd.	1,14,646	1,373.00	40.9	2.95	7.2%
Cipla Ltd.	1,13,988	1,411.00	39.3	3.22	8.2%
Mankind Pharma Ltd.	1,04,902	2,540.00	46.7	5.97	12.8%
Aurobindo Pharma Ltd.	1,03,572	1,800.00	26.0	2.63	10.1%
Jubilant Pharmova Limited	14,846	939.60	42.2	2.09	5.0%

StoxGud checklist: Neutral setup · 5/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month-3.6%

6 months-4.2%

1 year-17.3%

3Y CAGR+32.9%

5Y CAGR+9.1%

10Y CAGR+3.8%

50-day avg₹968.16

200-day avg₹942.87

RSI (14)50

FAQs

What is the share price of Jubilant Pharmova Limited?

Jubilant Pharmova Limited (JUBLPHARMA) closed at ₹939.60 on NSE on 06 Nov 2026.

What is the market cap of Jubilant Pharmova Limited?

₹14,846 crore at the latest close.

What is the P/E ratio of Jubilant Pharmova Limited?

42.2, on trailing-twelve-month earnings from its filings.

How fast is Jubilant Pharmova Limited growing?

Jubilant Pharmova Limited: revenue has compounded at 9.6% a year over three years. Latest-quarter revenue is up 17.3% year on year, profit down 45.1%.

How profitable is Jubilant Pharmova Limited?

On a trailing-twelve-month basis return on equity is 5.0%, return on capital employed 7.4%, operating margin 14.2%, net margin 4.1%.

How much debt does Jubilant Pharmova Limited have?

Jubilant Pharmova Limited is lightly geared: debt to equity is 0.45 with borrowings of ₹3,220 cr against cash of ₹1,267 cr (balance sheet of 2026-03-31). Operating profit covers interest 3.5 times.

Financials parsed from Jubilant Pharmova Limited's own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from MAR '18, annual from FY18, balance sheet from Sep '22. * = derived (full year or half year minus earlier quarters). Information only, not investment advice.